

# 1 **Estimating the impact of disruptions due to COVID-19 on HIV** 2 **transmission and control among men who have sex with men in** 3 **China**

4 Ross. D. Booton<sup>1, 2, \*, §</sup>, Gengfeng Fu<sup>3, \*</sup>, Louis MacGregor<sup>1</sup>, Jianjun Li<sup>3</sup>, Jason J. Ong<sup>4, 5, 6</sup>,  
5 Joseph D. Tucker<sup>4, 5, 7, 8</sup>, Katy M.E. Turner<sup>1</sup>, Weiming Tang<sup>4, 7, 8</sup>, Peter Vickerman<sup>1</sup>, Kate M.  
6 Mitchell<sup>2</sup>

7  
8 <sup>1</sup>University of Bristol, Bristol, United Kingdom

9 <sup>2</sup>MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, Imperial  
10 College London, London, United Kingdom

11 <sup>3</sup>Jiangsu provincial center for disease control and prevention, Nanjing, Jiangsu province, China

12 <sup>4</sup>Social Entrepreneurship to Spur Health (SESH) Global, Guangzhou, China

13 <sup>5</sup>Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United  
14 Kingdom

15 <sup>6</sup>Central Clinical School, Monash University, Melbourne, Australia

16 <sup>7</sup>University of North Carolina Project-China, Guangzhou, China

17 <sup>8</sup>University of North Carolina at Chapel Hill, Chapel Hill, United States

18 \* *Considered joint first author*

19 § *Correspondence: Dr. Ross D. Booton, Bristol Veterinary School, University of Bristol, Bristol, BS40 5DU,*  
20 [\*rdbooton@gmail.com\*](mailto:rdbooton@gmail.com)

21  
22 E-mail addresses of authors:

23 RDB: [rdbooton@gmail.com](mailto:rdbooton@gmail.com)

24 GF: [fugf@jscdc.cn](mailto:fugf@jscdc.cn)

25 LM: [louis.macgregor@bristol.ac.uk](mailto:louis.macgregor@bristol.ac.uk)

26 JL: [babbittle@jscdc.cn](mailto:babbittle@jscdc.cn)

27 JJO: [Jason.Ong@monash.edu](mailto:Jason.Ong@monash.edu)

28 JDT: [jdtucker@med.unc.edu](mailto:jdtucker@med.unc.edu)

29 KMET: [katy.turner@bristol.ac.uk](mailto:katy.turner@bristol.ac.uk)

30 WT: [Weiming\\_tang@med.unc.edu](mailto:Weiming_tang@med.unc.edu)

31 PV: [peter.vickerman@bristol.ac.uk](mailto:peter.vickerman@bristol.ac.uk)

32 KMM: [kate.mitchell@imperial.ac.uk](mailto:kate.mitchell@imperial.ac.uk)

33  
34 **Keywords:**

35 COVID-19 pandemic, men who have sex with men, modeling, HIV transmission, key and vulnerable  
36 populations, People's Republic of China

37 **Word count:**

38 **Abstract:** 344. **Main text:** 3604.

39 **Abstract**

40 **Introduction** The COVID-19 pandemic is impacting HIV care globally, with gaps in HIV  
41 treatment expected to increase HIV transmission and HIV-related mortality. We estimated  
42 how COVID-19-related disruptions could impact HIV transmission and mortality among men  
43 who have sex with men (MSM) in four cities in China.

44

45 **Methods** Regional data from China indicated that the number of MSM undergoing facility-  
46 based HIV testing reduced by 59% during the COVID-19 pandemic, alongside reductions in  
47 ART initiation (34%), numbers of sexual partners (62%) and consistency of condom use  
48 (25%). A deterministic mathematical model of HIV transmission and treatment among MSM  
49 in China was used to estimate the impact of these disruptions on the number of new HIV  
50 infections and HIV-related deaths. Disruption scenarios were assessed for their individual  
51 and combined impact over 1 and 5 years for a 3-, 4- or 6-month disruption period.

52

53 **Results** Our China model predicted that new HIV infections and HIV-related deaths would  
54 be increased most by disruptions to viral suppression, with 25% reductions for a 3-month  
55 period increasing HIV infections by 5-14% over 1 year and deaths by 7-12%. Observed  
56 reductions in condom use increased HIV infections by 5-14% but had minimal impact (<1%)  
57 on deaths. Smaller impacts on infections and deaths (<3%) were seen for disruptions to  
58 facility testing and ART initiation, but reduced partner numbers resulted in 11-23% fewer  
59 infections and 0.4-1.0% fewer deaths. Longer disruption periods of 4 and 6 months amplified  
60 the impact of combined disruption scenarios. When all realistic disruptions were modelled  
61 simultaneously, an overall decrease in new HIV infections was always predicted over one  
62 year (3-17%), but not over 5 years (1% increase-4% decrease), while deaths mostly increased  
63 over one year (1-2%) and 5 years (1.2 increase – 0.3 decrease).

64

65 **Conclusions** The overall impact of COVID-19 on new HIV infections and HIV-related  
66 deaths is dependent on the nature, scale and length of the various disruptions. Resources  
67 should be directed to ensuring levels of viral suppression and condom use are maintained to  
68 mitigate any adverse effects of COVID-19 related disruption on HIV transmission and  
69 control among MSM in China.

70

71

## 72 **Introduction**

73 Globally, 37.9 million people are living with HIV (PLWH) [1], with men who have sex with  
74 men (MSM) disproportionately affected [2]. In China, a recent systematic review indicated an  
75 HIV prevalence of 5.7% (95% CI:5.4-6.1%) among MSM, with increasing HIV prevalence in  
76 this group over time (2001-2018) [3]. Efforts to manage the HIV epidemic in China have  
77 been made increasingly difficult by the emergent COVID-19 pandemic [4,5], having  
78 significant potential to affect the HIV care continuum and patterns of sexual risk behaviour in  
79 numerous settings worldwide [6–10]. Close examination of this syndemic is a key issue for  
80 global public health [11].

81

82 Among PLWH in China - who already face high levels of HIV stigma, psychological  
83 distress, and suboptimal adherence to antiretroviral therapy (ART) [4] - the COVID-19  
84 pandemic has presented further barriers to HIV control [5]. Quarantine and social distancing  
85 reduce access to routine HIV testing which reduces the identification and treatment of new  
86 HIV infections [12]. Timely linkage to HIV services and initiation of ART have been  
87 affected during the COVID-19 pandemic, with many hospitals designated for treatment of  
88 COVID-19 suspending taking on new patients with HIV [4]. The COVID-19 pandemic has  
89 hindered ART, due to hospital visits being restricted from city lockdowns/traffic controls [4].  
90 In February 2020, a survey in China found 32.6% of PLWH were at risk of ART  
91 discontinuation and about half (48.6%) did not know where to get ART in the near future  
92 [13]. These gaps in HIV treatment could lead to increased HIV-related deaths and higher risk  
93 of HIV transmission. Conversely, MSM in other countries have reported having fewer sexual  
94 partners during periods of COVID-19-related lockdown, which may temporarily reduce HIV  
95 transmission [7].

96

97 Mathematical modelling can be used to capture the complexity of these changes and estimate  
98 the impacts of COVID-19 on HIV epidemiology. One modelling study of PLWH in Africa  
99 projected that a 6-month interruption in ART supply across 50% of the population on  
100 treatment could lead to a 60% increase in HIV-related deaths over a 1-year period [14].  
101 Another modelling study on low-and-middle-income countries (LMIC) projected that HIV-  
102 related deaths would increase by 10% over the next five years, with the greatest impact on  
103 mortality estimated to be from ART interruptions [15]. However, neither of these studies

104 used observed COVID-19 impact data to inform their modelled disruptions, which is  
105 essential for obtaining reliable projections for the true scale of COVID-19 disruptions.

106

107 To our knowledge no COVID-19 impact modelling has been published focussing on key  
108 populations, who are the main groups affected by HIV [16]. In addition, no model projections  
109 have to date incorporated observed data from the COVID-19 disruption. In this study, we  
110 addressed this by collating data on the impact of COVID-19 and resulting lockdown  
111 measures on HIV testing and treatment among PLWH, sexual risk behaviour and condom use  
112 among MSM in China. We used a deterministic model of HIV transmission and treatment  
113 among MSM in China to estimate the impact of these disruptions on new HIV infections and  
114 HIV-related deaths. We identified where HIV prevention and treatment efforts should be  
115 focussed to help mitigate potential adverse effects of COVID-19.

116

## 117 **Methods**

### 118 **Observed disruptions due to COVID-19 in China**

119 Estimates of changes in HIV testing (among MSM), treatment initiation and viral load  
120 suppression (among all PLWH) came from surveillance data from Jiangsu province (HIV  
121 testing/clinics), from the first quarter of 2019 and 2020 [17]. Estimates of changes in number  
122 of sexual partners and consistency of condom use came from an online survey conducted  
123 among MSM (N=731) across 31 provinces in China between 18/05/2020-02/06/2020, during  
124 the COVID-19 pandemic. From these data, we estimated the following percentage changes  
125 due to the disruption caused by COVID-19, compared to the pre-COVID period (before  
126 01/01/2020):

127

- 128 I. The number of MSM undergoing facility-based HIV testing in the first quarter of  
129 2019 was 6436 compared to 2641 in 2020, a reduction of 59% (95% CI:58-60%).
- 130 II. The number of PLWH initiating ART in the first quarter of 2019 was 315 compared  
131 to 208 in 2020, a reduction of 34% (95% CI:29-39%).
- 132 III. There was no change in viral suppression (VS) among PLWH. 95.3% (940/986; 95%  
133 CI:93.8-96.6%) of viral load tests showed VS in the first quarter of 2019, with similar  
134 numbers in 2020 (96.0%, 928/967; 95% CI:94.5-97.1%). The proportion of diagnosed  
135 PLWH who had a viral load test was similar in both years: 4.7% in the first quarter of

136 2019 and 4.3% in the first quarter of 2020. Note most viral load tests in this region are  
137 conducted in the 3<sup>rd</sup>/4<sup>th</sup> quarter.

138 IV. 62% (313/506) of MSM reported reduced numbers of sexual partners compared to the  
139 pre-pandemic period (among those who had male partners in the last six months).

140 V. 25% (126/506) of MSM used fewer condoms with their partners compared to the pre-  
141 pandemic period.

142

### 143 **Mathematical model**

144 We used a model of HIV testing/transmission/treatment among MSM in China which was  
145 previously developed to evaluate the long-term impact of an HIV self-testing intervention in  
146 four cities (Guangzhou/Shenzhen/Jinan/Qingdao) [18]. All individuals within the model are  
147 categorised by infection status, risk ( $\leq$ / $>$ two male anal sex partners in the last three months),  
148 anal sex role (always insertive/versatile/always receptive), infection stage  
149 (acute/CD4 $>$ 500/351-500/200-350/ $<$ 200 cells/ $\mu$ l), and diagnosed/ART status. Uninfected  
150 MSM enter the population upon sexual debut and leave through migration or non-HIV/HIV-  
151 related death. Those not on ART move into more advanced stages of infection, while those  
152 on ART do not; their mortality is modelled as a function of infection stage at ART initiation  
153 (Fig.S2).

154

155 Both facility-based and self-testing are modelled, and MSM are distinguished by whether or  
156 not they have previously tested. Those on ART who drop out re-enter the diagnosed  
157 compartments. HIV transmission occurs via anal sex between MSM at a rate which depends  
158 on HIV disease stage/ART coverage/V<sub>S</sub>/total partners/total sex acts/sexual role/condom  
159 efficacy and use. The model was calibrated to MSM city-level HIV epidemics, parameterised  
160 using demographic/behaviour data from CDC/trials, calibrated to local  
161 city/province/national-level estimates (“fitting metrics”) of HIV prevalence/ART  
162 coverage/diagnosis/incidence/population size [18]. The model was solved in R.3.5.1.  
163 Model/schematics (Figs.S2-3), parameters/fitting metrics (Table S6) and fitting metrics  
164 (Fig.S1) are given in the supplement.

165

### 166 **Base case scenario (no COVID-19)**

167 The model was run for five years until 01/01/2025 using the fitted model parameters, with all  
168 parameters constant at their 2019 values from 01/01/2020 onwards. These base case runs  
169 predicted the non-COVID-19 trajectory of HIV prevalence and care for each city.

170

## 171 **COVID-19-related disruption scenarios**

172 Disruption scenarios were implemented from 01/01/2020 and run for 3 months, after which  
173 all parameters were reset to their original pre-COVID-19 values. Comparisons of these  
174 scenarios with the base case were made over one (01/01/2021) and five years (01/01/2025).

175

176 The following *observed* disruption scenarios were based on the observed disruptions –  
177 reductions in:

- 178 A. facility-based HIV testing (59%)
- 179 B. ART initiation (34%)
- 180 C. number of sexual partnerships (31–62%)
- 181 D. condom use (12.5–25%)

182

183 Although data from Jiangsu province suggested no disruption to VS, disruptions in ART  
184 provision have been reported to the WHO [19]. We explored an additional *hypothetical*  
185 scenario where VS was reduced by 10% (consistent with reductions in ART access among  
186 MSM in United States [7]) and 25% (consistent with disruptions to ART uptake reported  
187 among PLWH in China [4]):

- 188 E. Reduction in VS of 10/25%

189

190 The data on sexual partnerships and condom use estimated the proportion of MSM having  
191 fewer partnerships/using condoms less frequently (not of their overall reductions). We  
192 sampled partnership and condom use parameters from uniform distributions with bounds of  
193 half-reported to full-reported reductions. Reductions in condom use were modelled as a  
194 reduction in the proportion of sex acts in which a condom is used. Reductions in HIV testing  
195 and ART initiations were modelled as reductions in the facility-based HIV testing rate and  
196 ART initiation rate, and reductions in partner numbers were modelled as reductions in  
197 numbers of partners per year (applied across all risk groups). VS reductions were modelled as  
198 increases in infectiousness and HIV-related mortality among those on ART, assuming a  
199 proportion (10%/25%) of virally suppressed MSM stop taking ART, having the same  
200 infectiousness and HIV-related mortality as individuals not on ART. No reduction in HIV  
201 self-testing rates were modelled, in line with local observations in Jiangsu.

202

203 We assessed the impact of each disruption (A,B,C,D,E) separately, and also assessed the  
204 combined impact of these disruptions occurring simultaneously ( $\pm$ scenario-E). The impacts  
205 of disruptions lasting 3, 4 and 6 months were assessed.

206

207 The outcome measures used to assess the disruption caused by COVID-19 were total and  
208 relative percentage change in new infections and HIV-related deaths, compared to the base  
209 case, non-COVID-19 scenario. These impacts were evaluated over 1-year (01/01/2020-  
210 01/01/2021) and 5-years (01/01/2020-01/01/2025). All impact measures were expressed as  
211 median values and 95% credible intervals (95% CrI), across the 100 selected parameter sets  
212 in each city, and across the 400 parameter sets from all cities.

213

214 We analysed the sensitivity of these scenarios (A,B,C,D,E) to different magnitudes of  
215 disruption (0,25,50,75,100%) over 1 and 5 years with a 3-month disruption. We plot the %  
216 change in new HIV infections and HIV-related deaths as a function of each individual  
217 disruption parameter.

218

## 219 **Results**

220 The percentage change in impact measures (new HIV infections and HIV-related deaths) did  
221 not vary between each city, with greater within-city variation across the scenarios. Therefore,  
222 all results are presented as the overall impact across four cities (Table S1,  
223 Guangzhou/Shenzhen/Jinan/Qingdao), with results for each city in the supplement (Tables  
224 S2-5).

225

### 226 **Single and combined 3-month disruptions**

227 Realistic disruptions to facility-based HIV testing, ART initiation and condom use were each  
228 estimated to lead to an increase in new HIV infections among MSM (Fig.1a, Tables S1-S5).  
229 Disruptions to condom use (scenario-D) lasting 3 months were predicted to lead to the largest  
230 overall relative increase in HIV infections, of 7.8% (95% CrI:4.5-13.8%) over one year  
231 (Fig.1a), with relative increases of 2.3% (1.7-2.9%) and 1.7% (1.2-2.4%) predicted over 1  
232 year for realistic 3-month disruptions to facility-based HIV testing (scenario-A) and ART  
233 initiations (scenario-B), respectively. Reductions in numbers of sexual partners (scenario-C)  
234 were predicted to reduce HIV infections, by a median 16.2% (11.1-23.2%) over one year  
235 among MSM following a 3-month disruption.

236

237 A hypothetical 10%/25% reduction in VS (E10/E25) would lead to increased numbers of  
238 HIV infections. 25% reductions in VS increased new HIV infections by 7.4% (4.7-14.0%)  
239 over one year given a 3-month disruption.

240

241 The effect of each disruption scenario on the relative percentage change in HIV infections  
242 was always smaller over five years than after one year (but not the absolute difference in HIV  
243 infections, which generally increased over 5 years), with a more rapid decrease in effect over  
244 5 years seen for disruptions to partnership numbers, condom use and VS (Fig.1a).

245

246 When all of the observed disruptions (A+B+C+D) were modelled simultaneously, a decrease  
247 in new HIV infections was always predicted over one year (median 8.7%, (2.8%-17.2%)), but  
248 over 5 years this impact reduced to a 1.6% (-0.6%-4.3%) decrease in new HIV infections due  
249 to the disruptions to HIV testing (increase 1.7%, 1.2%-2.4%) and ART initiation (increase  
250 1.1%, 0.7-1.8%) having a longer-lasting effect on ART outcomes, with ART taking longer  
251 post-disruption to return to pre-disruption levels.

252

253 HIV-related deaths were also predicted to increase following disruptions to HIV testing/ART  
254 initiations/condom use/VS (scenarios-A,B,D,E), and decrease following disruptions to  
255 partnerships (scenario-C) (Fig.1b, Tables S1-S5). Small impacts (<1%) on HIV-related  
256 deaths were predicted over one year for 3-month disruptions to HIV testing, partner numbers  
257 or condom use. Larger increases in HIV-related deaths were predicted to occur following 3-  
258 month disruptions to ART initiations – a 1.8% (1.5-2.0%) increase over one year–and,  
259 especially, VS – a 10.1% (7.6-12.7%) increase over one year following a 25% VS reduction.  
260 The observed disruptions together (A+B+C+D) resulted in 1.5% (1.1-1.8%) more HIV-  
261 related deaths over one year and 0.6% (-0.3-1.2%) over five years.

262

263 Including reductions of 10%/25% in levels of VS alongside the other, observed scenarios  
264 (A+B+C+D+E10, A+B+C+D+E25) always led to an increase in new HIV infections, and,  
265 particularly, an increase in HIV-related deaths, over a 1- or 5-year time horizon, compared to  
266 the observed scenarios (A+B+C+D) alone (Figs.1a,b).

267

268 **Sensitivity in disruption duration**



269 When comparing the impacts of two combined disruption scenarios (A+B+C+D and  
270 A+B+C+D+E25) for disruptions lasting 3/4/6 months, we found impacts on both new HIV  
271 infections and HIV-related deaths were approximately linear, with a 4-month disruption  
272 leading to around 34% greater impact than a 3-month disruption, and a 6-month disruption  
273 around two times the impact of a 3-month disruption, over both the 1- and 5-year time  
274 horizons (Fig.2).

275

### 276 **Impact in different cities**

277 The absolute numbers of predicted additional/prevented infections and deaths varied for each  
278 city (Tables S2-S5), related to differing MSM population sizes, but the percentage changes in  
279 infections and deaths did not vary substantially between cities (Fig.3, Tables S2-S5). For  
280 example, for scenario A+B+C+D, the overall predicted reduction in new HIV infections over  
281 one year varied from 8.7% (-2.8-17.2%) in Qingdao to 9.1% (2.5-15.0%) in Jinan, with far  
282 greater within-city than between-city uncertainty (Fig.3).

283

284 Over 5 years, realistic 3-month disruptions to HIV testing, ART initiations, sexual risk  
285 behaviour and condom use (scenario A+B+C+D) would lead to on average 3 fewer new HIV  
286 infections but 1 additional HIV-related death among MSM in Jinan and Qingdao, 6 fewer  
287 infections and 3 additional deaths in Guangzhou, and to 18 fewer HIV infections but 9  
288 additional HIV-related deaths among MSM in Shenzhen.

289

290 The combined hypothetical scenario (A+B+C+D+E) lasting for 3 months, over 5 years,  
291 would lead to an average 3 additional new HIV infections in Guangzhou, 7 in Shenzhen but  
292 no change in Jinan and Qingdao, with 11 additional HIV-related deaths in Guangzhou, 33 in  
293 Shenzhen and 3 in Jinan and Qingdao.

294

### 295 **Sensitivity in disruption magnitude**

296 Over 1 or 5 years, with a 3-month disruption, the relationship between the magnitude of the  
297 disruption (0,25,50,75,100%) and the projected impact was always linear (Fig.S4-5, Table  
298 S7-8), with higher values of % disruption leading to increases in new HIV infections and  
299 HIV-related deaths for four disruption parameters (facility testing/ART initiation/condom  
300 use/VS) but not for partnership disruption, (fewer infections and deaths).

301

302 For a 3-month disruption evaluated over a 1-year, theoretical disruption scenarios A-E50  
303 (affecting 50% of MSM) increased new HIV-infections by 1.8%, 2.4%, -16.7% (decrease),  
304 15.8% and 11.3% respectively, and increased HIV-related deaths by 0.1%, 2.5%, -0.4%  
305 (decrease), 0.5% and 18.2% respectively (Fig.S4, Table S7). If disruption scenarios affected  
306 100% of MSM (A-E100), then new HIV-infections were projected to increase to 3.7%, 4.9%,  
307 -30.2% (decrease for 95% affecting MSM – the model requires >0 partnerships), 38.7% and  
308 29.3% respectively. Scenarios A-E100 would also cause HIV related deaths to increase to  
309 0.3%, 5.3%, -0.8% (decrease – for 95% disruption), 1% and 35.7% respectively.

310

## 311 **Discussion**

312 Available data in this analysis suggests that the COVID-19 pandemic and measures  
313 undertaken against it have resulted in reduced rates of HIV testing and treatment among  
314 MSM in this region of China but have not so far had an impact on VS rates. Survey data also  
315 suggested MSM in China had fewer partners and used condoms less often during the  
316 COVID-19 pandemic. Using these data in our modelling analysis, simulating realistic 3-  
317 month disruptions to HIV testing, ART initiation, condom use and partner numbers, we  
318 found fewer new HIV infections are projected to occur among MSM in China over 2020 (9%  
319 fewer) than would have occurred in the absence of the COVID-19 pandemic, with a smaller  
320 decrease (2%) seen over 5 years. This decrease was largely due to reductions in sexual  
321 partner numbers counteracting a reduction in ART initiations and condom use. Our models  
322 do suggest these disruptions will lead to small increases in HIV-related deaths (2% over 1  
323 year and 1% over 5 years). When we also evaluated potential reductions in VS of 25%  
324 alongside these observed disruptions, we predicted a 4% decrease in new HIV infections and  
325 10% increase in HIV-related deaths over one year. When evaluating the effects of each  
326 individual disruption separately, new HIV infections were most adversely affected by  
327 disruptions in condom use and VS, and HIV-related deaths by reductions in VS. Therefore,  
328 our results suggest HIV prevention and treatment efforts should focus on maintaining use of  
329 condoms and VS among MSM in China to mitigate short- and long-term adverse effects of  
330 the COVID-19 disruption.

331

332 Although disruptions to VS had consequences for HIV incidence/mortality, data from Jiangsu  
333 [17] indicated no change in VS among PLWH due to COVID-19 disruption. Other surveys  
334 among PLWH in China indicate disruptions to ART access [4] which could lead to

335 reductions in VS. It is critically important to quantify such reductions in treatment access and  
336 VS among MSM in China, and we suggest that future surveys should focus their efforts on  
337 determining the true scale of the disruption to VS, which is likely to be delayed and could  
338 occur after observed treatment disruptions.

339

340 The length of disruption is also critical in determining the longer-term impacts of COVID-19.  
341 Throughout our main analysis we used a disruption length of 3 months, with sensitivity  
342 analyses (with longer 4/6-month disruptions) demonstrating a linear relationship between the  
343 duration of disruption and the change in both new HIV infections and HIV-related deaths,  
344 with a doubling in disruption duration leading to a doubling in the impact. When assessing  
345 the combined impact of the observed disruptions, the direction of the linear relationship was  
346 different for HIV-related deaths (positive – longer duration gave more deaths) and new HIV  
347 infections (negative – longer duration gave fewer new infections).

348

349 The absolute numbers of new HIV infections and HIV-related deaths varied between the four  
350 cities in China modelled, due to the different population sizes, epidemiology and care cascade  
351 in each city (reflected in data used for calibration [18]). However, the percentage change in  
352 impact measures did not vary between each city, with much greater within-city variation.  
353 This result is surprising, considering each city has different future projected HIV prevalence  
354 (5.0 – 12.2% in 2036, based on data specific to these cities [20] in Booton et al. [18]) and are  
355 in two different provinces (Guangdong/Shandong). Therefore, the impact predicted in this  
356 study is likely to be applicable to MSM within any city/region in China.

357

358 We may compare our results to other modelling studies predicting the potential impact of  
359 COVID-19 related disruption on HIV prevention and treatment. Jewell et al. [14] used  
360 multiple African models of 3 month disruptions affecting 50% from 01/04/2020, reporting  
361 increases in HIV incidence of <1% from the suspension of HIV testing (*compared to our*  
362 *prediction of 1-2% for 50% reductions in facility testing, scenario-A50, all scenarios in Table*  
363 *S7), <2% from no new ART initiations (2-4%, scenario-B50), 2-9% from the interruption of*  
364 *condom availability (12-33%, scenario-D50), 4-89% from ART interruption (9-31% for 50%*  
365 *reduction in VS, scenario-E50). Suspension of testing for 50% increased deaths by <1%*  
366 *(<1%, scenario-A50), ART initiation <2% (2-3%, scenario-B50) and condom availability 0%*

367 (0-1%, scenario-D50) with ART interruption causing an increase of 17-62% (14-25%,  
368 scenario-E50). Our results align well with these estimates, considering the different  
369 methodology/definitions of disruption/population (all adults/children, compared to solely  
370 MSM) and underlying models and data (different settings/treatment/condom use). This is a  
371 major strength of our study, the use of early data from China, to estimate data-driven (rather  
372 than theoretical) magnitudes of COVID-19-related disruptions. Another major strength of this  
373 study was performing our analysis on four separate cities from two distinct regions within  
374 China. In addition, our analysis involves various scenarios and the effects of combining these  
375 enables us to better understand the relative impact of different disruptions.

376

377 Generalising our results to LMIC should be done with consideration of the differences  
378 between China and the respective country. Early estimates of COVID-19 impacts on  
379 testing/treatment/sexual risk behaviour were available as China was the first centre of the  
380 COVID-19 pandemic, and as more data becomes available, other LMIC countries may report  
381 different survey data. Our modelling analysis was able to highlight which of these disruptions  
382 are likely to have the biggest negative impacts on HIV incidence and deaths, indicating  
383 disruptions which should be prioritised for monitoring and mitigation in other countries.

384

385 Our analysis has some limitations which should be acknowledged. Not all of the disruption  
386 estimates were MSM specific, and MSM may have had more substantial disruption when  
387 compared to other populations (MSM facility testing was reduced by 59%, compared to 29%  
388 for the entire population [17]). Therefore, we may have underestimated the disruption to ART  
389 initiations. The survey data only gave semi-quantitative estimates of disruptions to  
390 partnerships and condom use i.e. proportion of MSM having fewer partners and not the  
391 overall reduction in partner numbers. We accounted for this by exploring uncertainty in the  
392 reduction and sampling from a wider distribution of estimates. Further, the disruption  
393 estimates for testing/ART initiations/VIS came from Jiangsu, different to the cities we model  
394 (Guangdong/Shandong), and estimates for disruptions to partner numbers/condom use came  
395 from 31 provinces, meaning we may not have fully captured the impact of COVID-19 in each  
396 city. Finally, we have not modelled the direct impacts of COVID-19 infection. Future  
397 extensions work could include modelling the potential characteristics of co-infection between  
398 HIV and COVID-19.

399

## 400 **Conclusions**

401 The COVID-19 emergency is impacting HIV care worldwide, as face-to-face consultations  
402 and laboratory testing are reduced, drug and condom manufacture and transport are  
403 interrupted, and lockdowns affect peoples' ability to access testing or collect medicines. Gaps  
404 in HIV treatment could lead to increased deaths from HIV and further HIV transmission,  
405 placing further burdens upon healthcare systems. The overall impact of COVID-19 on new  
406 HIV infections and HIV-related deaths is expected to be low to moderate for MSM in China,  
407 but this is dependent on the scale and length of the various disruptions. Resources should be  
408 urgently directed to ensuring VS and condom use remain high in order to mitigate any  
409 adverse effects of COVID-19 disruption on HIV transmission and control among MSM in  
410 China.

411

## 412 **Competing interests**

413 KMM has received an honorarium from Gilead for speaking outside of the submitted work.  
414 All other authors have no competing interests.

415

## 416 **Authors' contributions**

417 Conception and design of the study: RDB, GF, JJO, JDT, KMET, WT, PV, KMM.  
418 Acquisition of data: GF, JL, WT. Mathematical modelling: RDB, LM, KMET, PV, KMM.  
419 Coding and simulations: RDB. Analysis and interpretation of results: RDB, GF, LM, JL, JJO,  
420 JDT, KMET, WT, PV, KMM. Writing and drafting of the manuscript: RDB, GF, LM, JL,  
421 JJO, JDT, KMET, WT, PV, KMM. Approval of the submitted manuscript: RDB, GF, LM,  
422 JL, JJO, JDT, KMET, WT, PV, KMM.

423

## 424 **Acknowledgements**

425 **Funding:** This work was supported by Global Public Health strand of the Elizabeth  
426 Blackwell Institute for Health Research, funded under the University of Bristol's QR GCRF  
427 strategy (ISSF3: 204813/Z/16/Z). This work was also supported by the US NIH (NIAID  
428 K24AI143471, 1R01AI114310) and the NIHR Health Protection Research Unit in  
429 Behavioural Science and Evaluation at the University of Bristol (award number  
430 NIHR200877). This work was also supported by Health Data Research UK, which is funded  
431 by the UK Medical Research Council, Engineering and Physical Sciences Research Council,

432 Economic and Social Research Council, National Institute for Health Research, Chief  
433 Scientist Office of the Scottish Government Health and Social Care Directorates, Health and  
434 Social Care Research and Development Division (Welsh Government), Public Health  
435 Agency (South Western Ireland), British Heart Foundation and Wellcome (award number  
436 CFC0129).

437

### 438 **Additional files**

439 Additional file 1: Supplement **Supplement.docx**

440 Information on file format. Further details of the mathematical model and full results.

441

442

### 443 **List of abbreviations**

444 HIV human immunodeficiency virus

445 COVID-19 the disease caused by the SARS-CoV-2 (2019-nCoV) coronavirus.

446 PLWH people living with HIV

447 MSM men who have sex with men

448 ART antiretroviral therapy

449 LMIC low- and middle-income countries

450 VS viral suppression

451 CrI credible interval

452 CI confidence interval

453 CDC centre for disease control

454

### 455 **References**

456 1. Joint United Nations Programme on HIV/AIDS (UNAIDS). World AIDS day 2019  
457 fact sheet. Glob HIV AIDS Stat. 2019;

458 2. Beyrer C, Baral SD, Van Griensven F, Goodreau SM, Chariyalertsak S, Wirtz AL, et  
459 al. Global epidemiology of HIV infection in men who have sex with men. *Lancet*.  
460 2012;380(9839):367–77.

461 3. Dong MJ, Peng B, Liu ZF, Ye QN, Liu H, Lu XL, et al. The prevalence of HIV among  
462 MSM in China: A large-scale systematic analysis. *BMC Infect Dis*. 2019;19(1):1000.


463 4. Sun S, Hou J, Chen Y, Lu Y, Brown L, Operario D. Challenges to HIV Care and  
464 Psychological Health During the COVID-19 Pandemic Among People Living with

- 465 HIV in China. *AIDS Behav.* 2020;(May 7):1–2.
- 466 5. Jiang H, Zhou Y, Tang W. Maintaining HIV care during the COVID-19 pandemic.  
467 *Lancet HIV.* 2020;7(5):e308–9.
- 468 6. Ridgway JP, Schmitt J, Friedman E, Taylor M, Devlin S, McNulty M, et al. HIV Care  
469 Continuum and COVID-19 Outcomes Among People Living with HIV During the  
470 COVID-19 Pandemic, Chicago, IL. *AIDS Behav.* 2020;(May 7):1–3.
- 471 7. Sanchez TH, Zlotorzynska M, Rai M, Baral SD. Characterizing the Impact of COVID-  
472 19 on Men Who Have Sex with Men Across the United States in April, 2020. *AIDS*  
473 *Behav.* 2020;24(7):2024–32.
- 474 8. Luis H, Fridayantara WD, Mahariski P, Wignall FS, Irwanto I, Gedela K. Evolving  
475 ART crisis for people living with HIV in Indonesia. *Lancet HIV.* 2020;7(6):e384–5.
- 476 9. Ponticiello M, Mwangi-Amumpaire J, Tushemereirwe P, Nuwagaba G, King R,  
477 Sundararajan R. “Everything is a Mess”: How COVID-19 is Impacting Engagement  
478 with HIV Testing Services in Rural Southwestern Uganda. *AIDS Behav.* 2020;(May  
479 25):1–4.
- 480 10. Santos GM, Ackerman B, Rao A, Wallach S, Ayala G, Lamontage E, et al. Economic,  
481 Mental Health, HIV Prevention and HIV Treatment Impacts of COVID-19 and the  
482 COVID-19 Response on a Global Sample of Cisgender Gay Men and Other Men Who  
483 Have Sex with Men. *AIDS Behav.* 2020;(Jul 11):1–11.
- 484 11. Shiao S, Krause KD, Valera P, Swaminathan S, Halkitis PN. The Burden of COVID-  
485 19 in People Living with HIV: A Syndemic Perspective. *AIDS Behav.*  
486 2020;24(8):2244–9.
- 487 12. Pinto RM, Park S. COVID-19 Pandemic Disrupts HIV Continuum of Care and  
488 Prevention: Implications for Research and Practice Concerning Community-Based  
489 Organizations and Frontline Providers. *AIDS Behav.* 2020;24(9):2486–9.
- 490 13. Guo W, Weng HL, Bai H, Liu J, Wei XN, Zhou K, et al. Quick community survey on  
491 the impact of COVID-19 outbreak for the healthcare of people living with HIV.  
492 *Zhonghua Liu Xing Bing Xue Za Zhi.* 2020;41(5):662–6.
- 493 14. Jewell BL, Mudimu E, Stover J, ten Brink D, Phillips AN, Smith JA, et al. Potential  
494 effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19:  
495 results from multiple mathematical models. *Lancet HIV.* 2020;
- 496 15. Hogan AB, Jewell BL, Sherrard-Smith E, Vesga JF, Watson OJ, Whittaker C, et al.  
497 Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-  
498 income and middle-income countries: a modelling study. *Lancet Glob Heal.* 2020;

- 499 16. UNAIDS. Topics: Key populations [Internet]. [cited 2020 Sep 28]. Available from:  
500 <https://www.unaids.org/en/topic/key-populations>
- 501 17. Shi L, Tang W, Hu H, Qiu T, Marley G, Lui X, et al. Impact of the COVID-19  
502 Pandemic on HIV Care Continuum in Jiangsu, China. Prepr with Lancet [Internet].  
503 2020; Available from: <http://dx.doi.org/10.2139/ssrn.3612033>
- 504 18. Booton RD, Ong JJ, Lee A, Liu A, Huang W, Wei C, et al. Modelling the impact of an  
505 HIV testing intervention on HIV transmission among men who have sex with men in  
506 China. medRxiv. 2020;
- 507 19. World Health Organization. Disruption in HIV, Hepatitis and STI services due to  
508 COVID-19 [Internet]. Global HIV, Hepatitis and STI Programmes. 2020. Available  
509 from: [https://www.who.int/docs/default-source/hiv-hq/disruption-hiv-hepatitis-sti-](https://www.who.int/docs/default-source/hiv-hq/disruption-hiv-hepatitis-sti-services-due-to-covid19.pdf?sfvrsn=5f78b742_6)  
510 [services-due-to-covid19.pdf?sfvrsn=5f78b742\\_6](https://www.who.int/docs/default-source/hiv-hq/disruption-hiv-hepatitis-sti-services-due-to-covid19.pdf?sfvrsn=5f78b742_6)
- 511 20. Tang W, Wei C, Cao B, Wu D, Li K, Lu H, et al. Crowdsourcing to expand HIV  
512 testing among men who have sex with men in China: A closed cohort stepped wedge  
513 cluster randomized controlled trial. PLoS Med. 2018;15(8):e1002645.  
514  
515



516 **Figures**




517

518 **Figure 1:** The percentage change in (a) new HIV infections and (b) HIV-related deaths under disruption  
 519 scenarios evaluated over a 1- and 5-year time horizon (blue and orange respectively) in four cities in China.


520 Bars indicate median values, while error bars show the 95% credible intervals for each scenario and time  
 521 horizon. Scenarios are as follows: A) Reduction in facility-based HIV testing (59%), B) Reduction in ART  
 522 initiation (34%), C) Reduction in number of sexual partnerships (31 – 62%), D) reduction in condom use (12.5 –  
 523 25%) E10) Reduction in viral suppression of 10%, E25) Reduction in viral suppression of 10%.

524



525

526 **Figure 2:** The percentage change in new HIV infections and HIV-related deaths for scenarios (a) A+B+C+D  
 527 and (b) A+B+C+D+E25 for varying disruption periods (3, 4 and 6 months) and time horizons (1- and 5-year) in  
 528 four cities in China. Dots indicate median values.



529

530 **Figure 3:** The percentage change in new HIV infections and HIV-related deaths for scenario A+B+C+D for  
531 different cities (Guangzhou, Shenzhen, Jinan and Qingdao), and time horizons (1- and 5-year). Bars indicate  
532 median values and error bars show the 95% credible intervals.

533